The role of lamotrigine in the treatment of epilepsy – a cases’ report Case report

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Mar 31, 2019
DOI: https://doi.org/10.24292/01.MF.0119.7
Keywords:
lamotrigine, epilepsy, pregnancy, mood disorders

Main Article Content

Magdalena Kowalska
Klinika Neurologii i Epileptologii, Samodzielny Publiczny Szpital Kliniczny im. prof. Witolda Orłowskiego Centrum Medycznego Kształcenia Podyplomowego w Warszawie

Abstract

In the article, we investigate the use of lamotrigine in patients required special caution during the epilepsy treatment. Lamotrigine provides optimal control of the disease before pregnancy, which gives a chance to maintain this state during pregnancy. Lamotrigine has not got a teratogenic effect, that’s why it can be administrated during pregnancy. In patients with comorbid mood disorders, lamotrigine is stabilizing neuronal membranes and inhibition of glutamate release, both cause the antidepressant and normothymic effect. This effect is so strong that currently, lamotrigine has a registered indication in the prevention of depressive episodes in patients with bipolar I disorder, in whom depressive episodes predominate.

Article Details

How to Cite
Kowalska, M. (2019). The role of lamotrigine in the treatment of epilepsy – a cases’ report. Medycyna Faktow (J EBM), 12(1(42), 40-43. https://doi.org/10.24292/01.MF.0119.7
Issue
Vol 12 No 1(42) (2019)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Yerby M.S.: Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology 2000; 55(5 supl. 1): S21-31; discussion S54-8.
2. Harden C.L., Hopp J., Ting T.Y. et al.: Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence- based review): obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73(2): 126-132. DOI: 10.1212/WNL.0b013e3181a6b2f8.
3. Tomson T., Battino D., Bonizzoni E. et al.: Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011; 10(7): 609-617. DOI: 10.1016/S1474-4422(11)70107-7.
4.Diav-Citrin O., Shechtman S., Zvi N. et al.: Is it safe to use lamotrigine during pregnancy? A prospective comparative observational study. Birth Defects Res. 2017; 109(15): 1196-1203. DOI: 10.1002/bdr2.1058.
5. Goldberg J.F., Freeman M.P., Balon R. et al.: The American Society of Clinical Psychopharmacology Survey of Psychopharmacologists’ practice patterns for the treatment od mood disorders. Depress Anxiety 2015; 32(8): 605-613. DOI: 10.1002/da.22378.
6. Charakterystyka produktu leczniczego Lamilept, listopad 2018 r.